Salud financiera de hoja de balance de Global Blood Therapeutics
Salud financiera controles de criterios 2/6
Global Blood Therapeutics tiene un patrimonio de los accionistas total de $118.4M y una deuda total de $581.9M, lo que sitúa su ratio deuda-patrimonio en 491.7%. Sus activos y pasivos totales son $870.4M y $752.1M respectivamente.
Información clave
491.7%
Ratio deuda-patrimonio
US$581.95m
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$517.16m |
| Patrimonio | US$118.36m |
| Total pasivo | US$752.08m |
| Activos totales | US$870.44m |
Actualizaciones recientes sobre salud financiera
Global Blood Therapeutics (NASDAQ:GBT) Is Making Moderate Use Of Debt
Jun 07
Is Global Blood Therapeutics (NASDAQ:GBT) Using Too Much Debt?
Feb 24Despite Lacking Profits Global Blood Therapeutics (NASDAQ:GBT) Seems To Be On Top Of Its Debt
Nov 03Global Blood Therapeutics (NASDAQ:GBT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Jul 08Is Global Blood Therapeutics (NASDAQ:GBT) A Risky Investment?
Mar 18Recent updates
Global Blood Therapeutics expects to complete Pfizer deal in early October
Sep 30Global Blood Therapeutics: Pfizer Acquisition Signals Increasing M/A Deals
Sep 16Pfizer said to have had bidding war with Johnson & Johnson for Global Blood
Aug 24What Pfizer Is Getting Through The Acquisition Of Global Blood Therapeutics
Aug 08Global Blood Therapeutics to expand access to its sickle cell disease treatment in Brazil
Jul 14GBT begins phase 2/3 clinical trial of GBT601 to treat sickle cell disease
Jun 29Global Blood Therapeutics: Powerhouse Of The Future
Jun 21Global Blood Therapeutics (NASDAQ:GBT) Is Making Moderate Use Of Debt
Jun 07Global Blood Therapeutics: Hitting A Growth Inflection
Apr 12Global Blood Therapeutics: Changing My Strategy After Recent Earnings
Mar 12Is Global Blood Therapeutics (NASDAQ:GBT) Using Too Much Debt?
Feb 24Global Blood Therapeutics: Revisiting A Stellar Grower
Dec 25IBI Research On Global Blood Therapeutics: Galvanized For Growth
Nov 30Despite Lacking Profits Global Blood Therapeutics (NASDAQ:GBT) Seems To Be On Top Of Its Debt
Nov 03Global Blood Therapeutics: It Might Be Time To Buy The Dip
Oct 24Global Blood Therapeutics: Attempting To Classify The Investment
Aug 07Global Blood Therapeutics (NASDAQ:GBT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Jul 08Shareholders May Not Be So Generous With Global Blood Therapeutics, Inc.'s (NASDAQ:GBT) CEO Compensation And Here's Why
Jun 12Global Blood Therapeutics announces employment inducement grants
Jun 04Global Blood Therapeutics: Increasing Specialization In SCD
May 09Is Global Blood Therapeutics (NASDAQ:GBT) A Risky Investment?
Mar 18Breakeven On The Horizon For Global Blood Therapeutics, Inc. (NASDAQ:GBT)
Feb 20
Did Business Growth Power Global Blood Therapeutics' (NASDAQ:GBT) Share Price Gain of 152%?
Jan 25Have Insiders Been Buying Global Blood Therapeutics, Inc. (NASDAQ:GBT) Shares?
Dec 29Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($640.0M) de GBT superan a sus pasivos a corto plazo ($93.1M).
Pasivo a largo plazo: Los activos a corto plazo ($640.0M) de GBT no cubren sus pasivos a largo plazo ($659.0M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: La relación deuda neta-capital de GBT (54.7%) se considera alta.
Reducción de la deuda: No se dispone de datos suficientes para determinar si el ratio deuda-patrimonio de GBT se ha reducido en los últimos 5 años.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: GBT tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.
Pronóstico de cash runway: Datos insuficientes para determinar si GBT tiene suficiente cash runway en caso de que su flujo de caja libre siga creciendo o disminuyendo basado en tasas históricas.